MycoBiomDB – Record Details (MyCo_3506)

Biomarker Record Details

Database ID: MyCo_3506
DB IDMyCo_3506
TitleFractional exhaled nitric oxide, a potential biomarker for evaluating glucocorticoids treatment and prognosis in allergic bronchopulmonary aspergillosis
Year2024
PMID38777120
Fungal Diseases involvedAllergic bronchopulmonary aspergillosis
Associated Medical ConditionNone
GenusAspergillus
Speciesfumigatus
OrganismAspergillus fumigatus
Ethical StatementThe study was approved by the ethics committee of Shanghai Pulmonary Hospital (numbers K18-153 and K17-134).
Site of InfectionNone
Opportunistic invasiveNone
Sample typeNone
Sample sourceExhaled air
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NameFeNO
Biomarker Full NameFractional exhaled nitric oxide
Biomarker TypePrognostic
BiomoleculeVolatile
Geographical LocationChina
Cohort58 patients were enrolled in the retrospective study.
Cohort No.58
Age Group54.6±16.5
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismAllergic bronchopulmonary aspergillosis (ABPA) is a complex pul- monary allergic disease characterized by poor asthma control, hemoptysis, and mucous blockage in lung images. Immunologic reactions mediated against Aspergillus fumigatus are believed to be the main cause. The global burden of ABPA potentially reached 5 mil- lion people, which is more than previously expected. The clinical heterogeneity associated with ABPA poses challenges in providing timely treatment during the early stages of the disease, potentially leading to complications such as bronchiectasis and pulmonarybrosis.
TechniqueAnalytic
Analysis MethodFractional exhaled nitric oxide analysis
ELISA kitsNone
Assay DataNone
Validation Techniques usedFractional exhaled nitric oxide analysis
Up Regulation Down RegulationIncrease/Decrease
Sequence DataNone
External LinkNone